Considerations in the development of nonhuman primate models of combination antiretroviral therapy for studies of AIDS virus suppression, residual virus, and curative strategies - Wikidata - wikimedia - TriplyDB

Considerations in the development of nonhuman primate models of combination antiretroviral therapy for studies of AIDS virus suppression, residual virus, and curative strategies

Considerations in the development of nonhuman primate models of combination antiretroviral therapy for studies of AIDS virus suppression, residual virus, and curative strategies

http://www.wikidata.org/entity/Q26825814

about

Animal Models for HIV Cure Research Animal models in HIV cure research Multi-dose Romidepsin Reactivates Replication Competent SIV in Post-antiretroviral Rhesus Macaque Controllers Effects of treatment with suppressive combination antiretroviral drug therapy and the histone deacetylase inhibitor suberoylanilide hydroxamic acid; (SAHA) on SIV-infected Chinese rhesus macaques Latency reversal and viral clearance to cure HIV-1.Why primate models matter.Effect of suberoylanilide hydroxamic acid (SAHA) administration on the residual virus pool in a model of combination antiretroviral therapy-mediated suppression in SIVmac239-infected indian rhesus macaques.Short Communication: Comparative Evaluation of Coformulated Injectable Combination Antiretroviral Therapy Regimens in Simian Immunodeficiency Virus-Infected Rhesus Macaques.Elevated Plasma Viral Loads in Romidepsin-Treated Simian Immunodeficiency Virus-Infected Rhesus Macaques on Suppressive Combination Antiretroviral Therapy.Specific pathogen free macaque colonies: a review of principles and recent advances for viral testing and colony management.Long-term multilineage engraftment of autologous genome-edited hematopoietic stem cells in nonhuman primates.Highlights from the Keystone Symposium on HIV Persistence 2015: 26-30 April 2015, Boston, Massachusetts, USA Mechanistic differences between HIV-1 and SIV nucleocapsid proteins and cross-species HIV-1 genomic RNA recognition.A cure for AIDS: a matter of timing?Wake me up before you go: A strategy to reduce the latent HIV reservoir.

P2860

Q26767476-F26A8B07-4E82-46D7-AA40-FCC34F661B27 Q26853069-061797A6-9717-4A4C-A465-4615AD10F1A8 Q27312050-22A09B2F-58F2-41F4-9C88-964846A92E2A Q28540858-E3FA2089-5BA5-40EC-957D-A49FA4B3DF25 Q30248766-64E93A58-795E-44F2-892D-6C8951239E70 Q30417520-3049D556-4DA2-4083-9F31-FD9101CF5573 Q34596417-38B9C461-3636-4887-BB47-D56111C46138 Q36601857-37E43D69-1531-4FA7-AF4B-0101004AA563 Q36644877-874417DD-46F3-445D-887F-1151BFA8741E Q36711648-05877546-0C4E-45D1-9F38-EF767E228869 Q36920437-0A511942-B38D-44D6-A7A1-6295A2532FD0 Q37098393-E984CEC2-F950-4893-8C6F-21D548F681D8 Q37543482-1CBCCD38-47F9-4121-BD93-4B47DE18FBF3 Q38165451-8C7CBCB3-28A8-4C6F-8E9A-5AE6AC16528A Q45874441-62529474-B7BF-423A-B531-27F510F5F636

P2860

Considerations in the development of nonhuman primate models of combination antiretroviral therapy for studies of AIDS virus suppression, residual virus, and curative strategies

http://www.wikidata.org/entity/Q26825814

description

2013 nî lūn-bûn

@nan

2013 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Considerations in the developm ...... virus, and curative strategies

@ast

Considerations in the developm ...... virus, and curative strategies

@en

Considerations in the developm ...... virus, and curative strategies

@nl

type

label

Considerations in the developm ...... virus, and curative strategies

@ast

Considerations in the developm ...... virus, and curative strategies

@en

Considerations in the developm ...... virus, and curative strategies

@nl

prefLabel

Considerations in the developm ...... virus, and curative strategies

@ast

Considerations in the developm ...... virus, and curative strategies

@en

Considerations in the developm ...... virus, and curative strategies

@nl

P1433

Q26825814-4EB5D27D-207B-4AC0-BA28-142088400291

P1476

Q26825814-52C896C7-8BAA-4B70-AAB9-58DB7AB1D1EC

P2093

Q26825814-683AD66B-176B-46C1-BEA2-A6A685071DCA

Q26825814-A5212DB0-5859-4BEA-9E67-D91AF9758ABC

P2860

Q26825814-072EF854-3E3F-4D76-93BB-62A3424496BC

Q26825814-093424BB-B547-4D5A-8773-906B06E6ABD2

Q26825814-0B6DE12C-DE4F-47D0-8D86-FDE1B08B7B02

Q26825814-0B96450D-EFBC-42C0-835E-F77A26B1DC02

Q26825814-0E67F0B9-5C66-41D0-8F7B-070755DCEEC4

Q26825814-114C1ACD-6557-4033-A815-FE48788A846A

Q26825814-1180096E-872E-4869-A498-9FA6BC837F65

Q26825814-13C9908C-7D26-4D0E-9158-CC7A0433E4FF

Q26825814-15227168-B4A9-406E-9CBC-DC39598E67BD

Q26825814-1AE069FA-9B8A-43BE-B85D-3D55F8236253

P304

Q26825814-E7F0EAC8-8ABD-4B67-8193-BBE98E5403EC

P31

Q26825814-844FBAA9-70D8-4CCF-9B2E-5CAD3BA67D03

P3181

Q26825814-378BB0C5-ACFC-4CBD-B442-B2C3051DEAD9

P356

Q26825814-AC5FC7D7-E7DC-4C67-AC33-9BFDEB260C9E

P407

Q26825814-9E03839F-B333-4CAF-8931-109F7E886CDD

P433

Q26825814-90D39E83-F0F9-40DA-A751-378E2DE832CC

P478

Q26825814-11F04BAD-4D08-411C-8250-385FEC5DACC8

P577

Q26825814-CDC67732-91C4-4275-A0D8-A0CAB9F1871F

P698

Q26825814-801A4155-DBD8-4195-A4BB-1241F3C5F5B7

P921

Q26825814-015C0277-1F06-4A72-9055-1B5AA9C5CB08

Q26825814-2A16E8DE-0BAE-402E-A4D8-096EDD8A0B44

Q26825814-5F44A967-62C1-402A-9BD7-5C4303DEC728

P932

Q26825814-18284842-F3E8-4012-9176-8C21A1D3CAA9

P3181

P356

COH.0B013E328361CF40

P1433

Current Opinion in HIV and AIDS

P1476

Considerations in the developm ...... virus, and curative strategies

@en

P2093

Gregory Q. Del Prete

http://www.w3.org/2001/XMLSchema#string

Jeffrey D. Lifson

http://www.w3.org/2001/XMLSchema#string

P2860

Redefining the viral reservoirs that prevent HIV-1 eradication

A tonsillar PolyICLC/AT-2 SIV therapeutic vaccine maintains low viremia following antiretroviral therapy cessation

A highly intensified ART regimen induces long-term viral suppression and restriction of the viral reservoir in a simian AIDS model

ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia

Early antiretroviral therapy during primary HIV-1 infection results in a transient reduction of the viral setpoint upon treatment interruption

Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation

Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy

Recovery of replication-competent HIV despite prolonged suppression of plasma viremia

Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection

Response of a simian immunodeficiency virus (SIVmac251) to raltegravir: a basis for a new treatment for simian AIDS and an animal model for studying lentiviral persistence during antiretroviral therapy.

P304

262-72

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

3509019

http://www.w3.org/2001/XMLSchema#string

P356

10.1097/COH.0B013E328361CF40

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P577

2013-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23698559

http://www.w3.org/2001/XMLSchema#string

P921

antiretroviral drug

P932

3939607

http://www.w3.org/2001/XMLSchema#string